title: Intensive insulin therapy for preventing postoperative infection in patients with traumatic brain injury: A randomized controlled trial.
abstract: OBJECTIVE
  To assess the effect of intensive insulin therapy (IIT) for preventing postoperative infection in patients with traumatic brain injury (TBI).
  
  
  METHODS
  In total, 88 patients with TBI were randomly divided into 2 groups, 44 in each group. One group (group ITT) received IIT and the other group (group CIT) received conventional insulin therapy (CIT). This study was conducted between February 2013 and January 2016. Outcomes included infection rate, mortality, and neurological outcome (measured by the Glasgow Outcome Scale [GOS]).
  
  
  RESULTS
  A total of 81 patients completed the study. IIT showed greater efficacy than CIT, with a decreased infection rate in the IIT group compared to the CIT group (31.9% vs 52.3%, P = 0.03), and also a reduced duration of stay in intensive care unit (ICU) (IIT group, 4.5 ± 2.1 days vs CIT group, 5.7 ± 2.8 days, P = 0.02). In addition, a significant difference in scores on the GOS scale was observed between the 2 groups (P = 0.04). The mortality rates in hospital and at the 26-week follow-up were similar between the 2 groups.
  
  
  CONCLUSIONS
  IIT leads to a reduced infection rate, shorter stays in ICU, and improved neurological outcome.
authors.affiliation: Department of Neurosurgery (Intensive Care Unit) Department of Neurosurgery, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Jin-Ping
authors.initials: JP
authors.lastname: Li
authors.forename: Ying-Lun
authors.initials: YL
authors.lastname: Song
authors.forename: Qi-Huang
authors.initials: QH
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000070642:Brain Injuries, Traumatic / Q000097:blood* / Q000150:complications / Q000401:mortality / Q000601:surgery; D002681:China / Q000453:epidemiology; D003422:Critical Care / Q000379:methods; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin